MINERALYS THERAPEUTICS, INC. (MLYS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in CapitalUSD $1.29B; Retained Earnings (Accumulated Deficit)USD $-737.58M; Stockholders' Equity Attributable to ParentUSD $550.92M.
- 2026-03-31: Common Stock, Value, IssuedUSD $8.00K; Additional Paid in CapitalUSD $1.13B; Retained Earnings (Accumulated Deficit)USD $-496.51M; Stockholders' Equity Attributable to ParentUSD $638.14M.
- 2025-12-31: Common Stock, Value, IssuedUSD $8.00K; Additional Paid in CapitalUSD $1.10B; Retained Earnings (Accumulated Deficit)USD $-457.17M; Stockholders' Equity Attributable to ParentUSD $646.69M.
- 2025-09-30: Common Stock, Value, IssuedUSD $8.00K; Additional Paid in CapitalUSD $1.00B; Retained Earnings (Accumulated Deficit)USD $-424.94M; Stockholders' Equity Attributable to ParentUSD $576.43M.
MINERALYS THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9.00K | $1.29B | $-737.58M | $550.92M | (m) | 3 month · $7.36M |
| 2026-03-31 | $8.00K | $1.13B | $-496.51M | $638.14M | (m) | 3 month · $6.55M |
| 2025-12-31 | $8.00K | $1.10B | $-457.17M | $646.69M | (m) | 12 month · $19.32M |
| 2025-09-30 | $8.00K | $1.00B | $-424.94M | $576.43M | (m) | 3 month · $5.84M |
| 2025-06-30 | $6.00K | $701.55M | $-388.00M | $313.55M | 3 month · $46.00K | 3 month · $4.55M |
| 2025-03-31 | $6.00K | $686.28M | $-344.73M | $341.56M | 3 month · $12.51M | 3 month · $3.65M |
| 2024-12-31 | $5.00K | $493.77M | $-302.52M | $191.26M | 12 month · $3.94M | 12 month · $11.34M |
| 2024-09-30 | $5.00K | $490.50M | $-253.57M | $236.93M | (m) | 3 month · $3.14M |
| 2024-06-30 | $5.00K | $487.32M | $-197.23M | $290.10M | (m) | 3 month · $2.87M |
| 2024-03-31 | $5.00K | $484.26M | $-156.22M | $328.05M | 3 month · $3.94M | 3 month · $2.19M |
| 2023-12-31 | $4.00K | $365.86M | $-124.71M | $241.15M | (m) | 12 month · $5.06M |
| 2023-09-30 | $4.00K | $364.33M | $-100.32M | $264.01M | (m) | 3 month · $1.58M |
| 2023-06-30 | $4.00K | $362.56M | $-77.56M | $285.01M | (m) | 3 month · $1.28M |
| 2023-03-31 | $4.00K | $361.29M | $-65.42M | $295.88M | (m) | 3 month · $749.00K |
| 2022-12-31 | $1.00K | $540.00K | $-52.81M | $-52.27M | (m) | 12 month · $455.00K |
| 2022-09-30 | (m) | (m) | (m) | $-43.41M | (m) | 3 month · $192.00K |
| 2022-06-30 | (m) | (m) | (m) | $-36.93M | (m) | 3 month · $26.00K |
| 2022-03-31 | (m) | (m) | (m) | $-30.48M | (m) | 3 month · $19.00K |
| 2021-12-31 | (m) | (m) | (m) | $-22.93M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |